Navigation Links
Pediatric Researchers Find Possible 'Master Switch' Gene in Juvenile Arthritis
Date:7/1/2008

PHILADELPHIA, July 1 /PRNewswire-USNewswire/ -- Researchers have found that a gene region known to play a role in some varieties of adult rheumatoid arthritis is also present in all types of childhood arthritis. The researchers say the responsible gene may be a "master switch" that helps turn on the debilitating disease.

Researchers at The Children's Hospital of Philadelphia reported on the link between the gene region and juvenile idiopathic arthritis (JIA), formerly called juvenile rheumatoid arthritis. The genetic variant is on chromosome 9 in a region housing two genes, TRAF1 and C5. The TRAF1 gene codes for a protein that regulates tumor necrosis factor, a chemical strongly associated with JIA. However, the researchers say further study is needed to determine whether the TRAF1 gene or the C5 gene is altered in the disease.

The study appears in the July 2008 issue of Arthritis & Rheumatism. Lead authors are Terri H. Finkel, M.D., Ph.D.; Hakon Hakonarson, M.D. Ph.D., director of the Center for Applied Genomics; and Edward M. Behrens, M.D., all of Children's Hospital.

"There are only a few genes that may act as master switches like this to regulate autoimmune diseases," said Finkel, the chief of Rheumatology at Children's Hospital. "This switch we discovered probably has to be an 'ON' gene and when it interacts with other genes and environmental triggers, a child may get juvenile arthritis."

The study compared 67 Caucasian patients being treated for JIA to 1,952 healthy Caucasian control subjects recruited within the hospital's patient network. While the cause of JIA is unknown, results from this study back up past research that shows arthritis arises in a genetically susceptible individual due to environmental factors.

About 300,000 children in the U.S. have JIA, of which about 1,500 children are seen at Children's Hospital. JIA is the inflammation of the lining tissues of a joint and often causes stiffness and pain. While there is no cure for JIA, medicines and physical therapy can help maintain movement and reduce swelling and pain. Researchers have previously identified seven subtypes of JIA.

"We think this finding may be a clue to the specific disease pathway that leads to arthritis," said Behrens, a pediatric rheumatologist at Children's Hospital. "We currently use medicines called tumor necrosis factor blockers to treat children with JIA. However, not all children respond to these drugs, and other children may develop severe allergic reactions and other side effects. If we can fully identify all the genes that interact with environmental risk factors, we might develop more targeted treatments with fewer side effects."

"The high-resolution genome-wide association approach has very markedly enhanced our ability to identify disease genes in complex disorders such as JIA, and what is remarkable about this discovery is that it appears there may be a common genetic factor predisposing to all seven forms of the disease," said Dr. Hakonarson.

The study was supported by an Institutional Research Development Award from Children's Hospital and development research awards from the Cotswold Foundation, the Nickolett Fund, and the Arthritis Foundation of Eastern Pennsylvania.

Other authors are Jonathan P. Bradfield, B.S.; Cecilia E. Kim; LeKenya Linton, R.N., A.S.; Tracy Casalunovo, M.S.; Edward C. Frackelton, B.A.; Erin Santa B.A.; F. George Otieno, M.S.; Joseph T. Glessner, M.S.; Rosetta M. Chiavacci, B.S.N., and Struan F.A. Grant, Ph.D. All are from the Children's Hospital of Philadelphia.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Contact:

Media Relations Specialists

John Ascenzi

(267) 426-6055

Juliann Walsh

(267) 426-6054


'/>"/>
SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
2. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
3. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4. New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting
5. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
6. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
7. Curemark Appoints Preeminent Pediatrics Gastroenterologist
8. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
9. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
10. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
11. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... -- Enterin Inc., a privately-held CNS pharmaceutical company based in ... treat Parkinson,s disease (PD), has enrolled the first patient in ... controlled, multicenter study involving patients with PD and taking place ... a 9-to-12-month period. The first stage is open label and ... sites include Denver , Boca ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
Breaking Medicine Technology:
(Date:5/29/2017)... ... May 29, 2017 , ... A New York high ... 6 month test of the effectiveness of Artificial Intelligence (AI) in helping nudge men ... health game,’ said Wayne Hartrick, President of the Canadian Men’s Health Foundation (CMHF), whose ...
(Date:5/28/2017)... Winter Haven, FL (PRWEB) , ... May 28, ... ... Physician Partners of America (PPOA), is proud to announce that Sheldon K. Cho, ... on comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques ...
(Date:5/27/2017)... ... ... From May 21-23, hearing healthcare professionals gained a competitive edge with training ... Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s technology partner, Oticon ... to help them stay ahead in the industry. At the event, EarQ members learned ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... a new educational seminar to focus on current legislative activity and the latest ... begin at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. ...
(Date:5/26/2017)... Nevada (PRWEB) , ... May 26, 2017 , ... ... produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed ... conference applications. “We are thrilled to partner with Cupron® to provide customers ...
Breaking Medicine News(10 mins):